COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00657033
Recruitment Status : Completed
First Posted : April 14, 2008
Last Update Posted : October 14, 2013
Information provided by (Responsible Party):

Brief Summary:
Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: Levitra (Vardenafil, BAY38-9456) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 229 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Parallel Group, Multi-center Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction, and Their Female Partners' Sexual Quality of Life.
Study Start Date : October 2003
Actual Study Completion Date : August 2004

Arm Intervention/treatment
Experimental: Arm 1 Drug: Levitra (Vardenafil, BAY38-9456)
BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.

Experimental: Arm 2 Drug: Placebo
Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment

Primary Outcome Measures :
  1. The primary measures of efficacy in this study will be improved success of erection maintenance in men with ED and improvement in female partner's sexual quality of life. [ Time Frame: Weeks 0 -12 ]

Secondary Outcome Measures :
  1. SEP3 at weeks 4 and 12 of treatment compared to placebo. [ Time Frame: Weeks 4 and 12 ]
  2. Additional Patient Diary questions at 4 weeks, 8 weeks, 12 weeks, LOCF, and over entire treatment period compared to placebo. Per-subject success rates will be calculated as the number of successes divided by the number of sexual attempts with a resp [ Time Frame: Weeks 4, 8 and 12 ]
  3. Global assessment question (GAQ) at weeks 4 and 12 of treatment compared to placebo [ Time Frame: Weeks 4 and 12 ]
  4. Global confidence question (GCQ) at 12 weeks of treatment compared to placebo. [ Time Frame: Week 12 ]
  5. The score for the IIEF questionnaire EF domain (IIEF-EF) at weeks 4, 12, and LOCF of treatment compared to placebo [ Time Frame: Weeks 4 and 12 ]
  6. Scores from the Treatment Satisfaction Scale (TSS) -- Subject Active Medication module at week 12 and LOCF of treatment compared to placebo. The TSS is a self-report measure of subject and partner's satisfaction with various aspects of erectile function [ Time Frame: Week 12 ]
  7. Scores from the mSLQQ-QOL at week 12 and LOCF of treatment compared to placebo [ Time Frame: Week 12 ]
  8. Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25) at week 12 of treatment compared to placebo. [ Time Frame: Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males who have had ED for at least six months according to the National Institutes of Health (NIH) Consensus Conference December 7-9, 1992 (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
  • Stable, heterosexual relationship for more than 6 months.
  • Males 18 years, and older.
  • Written informed consent obtained.
  • The subject and his female partner must make at least four attempts at sexual intercourse on four separate days during the untreated baseline period (according to the answer to the following question in the Patient Diary: "Was sexual activity initiated with the intention of intercourse?").
  • At least 50% of attempts at sexual intercourse during the untreated baseline period must be unsuccessful, according to the following questions from the subject diary (at least one question should be answered "No"): "Were you able to achieve at least some erection (some enlargement of the penis)?"; "Were you able to insert your penis in your partner's vagina?"; "Did your erection last long enough for you to have successful intercourse?".

Exclusion Criteria:

A) Previous or current medical conditions:

  • Any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the Investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
  • Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) which, in the Investigator's opinion, would significantly impair erectile function.
  • Primary hypoactive sexual desire.
  • Spinal cord injury.
  • History of surgical prostatectomy (excluding TURP).
  • Retinitis pigmentosa.
  • Unstable angina pectoris.
  • History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months.
  • Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate ≥ 100 bpm).
  • Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
  • Clinically significant chronic haematological disease which may lead to priapism such as sickle cell anemia and leukemia.
  • Bleeding disorder.
  • Significant active peptic ulcer disease.
  • Resting hypotension (a resting systolic blood pressure of < 90 mm Hg) or hypertension (a resting systolic blood pressure > 170 mm Hg or a resting diastolic blood pressure > 110 mm Hg).
  • History of malignancy within the past 5 years (other than squamous or basal cell skin cancer).
  • NYHA Class III and IV heart failure.
  • History of positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C.
  • Symptomatic postural hypotension within 6 months of visit 1.

B) Concomitant medication:

  • Subjects who are taking nitrates or nitric oxide donors.
  • Subjects who take anticoagulants, except for antiplatelet agents.
  • Subjects who are taking androgens.
  • Subjects who are taking anti-androgens.
  • Subjects who are taking the following inhibitors of cytochrome P450 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
  • Subjects who have received any investigational drug (including placebo) within 30 days of Visit 1.
  • Use of any treatment for ED within 7 days of visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking alpha blockers

C) Abnormal laboratory values:

  • Subjects who have a serum total testosterone level more than 25% below the age-adjusted lower limit of normal according to the range of the testing laboratory.
  • Subjects with a serum creatinine > 3.0 mg/dl.
  • Elevation of AST and/or ALT > 3 times the upper limit of normal.
  • Diabetic subjects with an HbA1c>12%.

D) Other Exclusion Criteria:

  • Subjects age 65 or older who in the judgment of the investigator can not be started on a 10 mg dose
  • Subjects with a history of unresponsiveness to any PDE 5 Inhibitor treatment due to lack of efficacy or significant side effects leading to discontinuation of the PDE 5 Inhibitor treatment.
  • Subjects unwilling to cease use of vacuum devices, intracavernosal injections, Viagra® or other therapy for ED during the study.
  • Unwillingness of the subject or his partner to make 4 attempts at sexual intercourse on four separate days during the untreated baseline period.
  • Subjects with known hypersensitivity to Vardenafil, Bay 38-9456 (also known as SB-782528) or any component of the investigational medication.
  • Subjects who are illiterate or unable to understand the questionnaires or the Patient Diary.
  • Partners who are illiterate or unable to understand the questionnaires.
  • Subjects who are unwilling or unable to complete the Patient Diary.
  • Subjects or partners who, in the opinion of the investigator, would be non-compliant with the visit schedule of study procedures.
  • Subjects unwilling to refrain from consuming grapefruit juice or products containing grapefruit juice with study medication (Canada only).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00657033

Layout table for location information
United States, Arizona
Phoenix, Arizona, United States, 85023
United States, California
Beverly Hills, California, United States, 90212
Irvine, California, United States, 92618-3603
Newport Beach, California, United States, 92660
San Bernardino, California, United States, 92404
San Diego, California, United States, 92101
San Diego, California, United States, 92128
United States, Connecticut
Trumbull, Connecticut, United States, 06611
United States, Florida
Jacksonville, Florida, United States, 32257
United States, Georgia
Riverdale, Georgia, United States, 30274
United States, Maryland
Greenbelt, Maryland, United States, 20770
Lutherville, Maryland, United States, 21093
United States, New Jersey
Lawrenceville, New Jersey, United States, 08648
New Brunswick, New Jersey, United States, 08901
United States, New York
New York, New York, United States, 10016
United States, North Carolina
Charlotte, North Carolina, United States, 28209
Statesville, North Carolina, United States, 28677
Wilmington, North Carolina, United States, 28412
Canada, Alberta
Calgary, Alberta, Canada, T2V 4R6
Canada, Ontario
Barrie, Ontario, Canada, L4M 4S5
Burlington, Ontario, Canada, L7N 3V2
Kitchener, Ontario, Canada, N2M 5N4
London, Ontario, Canada, N6A 4V2
Oakville, Ontario, Canada, L6H 3P1
Canada, Saskatchewan
Saskatoon, Saskatchewan, Canada, S7M 0Z9
Victoria, Canada, V8T 5G1
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00657033    
Other Study ID Numbers: 100519
First Posted: April 14, 2008    Key Record Dates
Last Update Posted: October 14, 2013
Last Verified: October 2013
Keywords provided by Bayer:
Erectile Dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents